Search Results - "Ishijima, Mikako"

Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients by Osa, Akio, Uenami, Takeshi, Koyama, Shohei, Fujimoto, Kosuke, Okuzaki, Daisuke, Takimoto, Takayuki, Hirata, Haruhiko, Yano, Yukihiro, Yokota, Soichiro, Kinehara, Yuhei, Naito, Yujiro, Otsuka, Tomoyuki, Kanazu, Masaki, Kuroyama, Muneyoshi, Hamaguchi, Masanari, Koba, Taro, Futami, Yu, Ishijima, Mikako, Suga, Yasuhiko, Akazawa, Yuki, Machiyama, Hirotomo, Iwahori, Kota, Takamatsu, Hyota, Nagatomo, Izumi, Takeda, Yoshito, Kida, Hiroshi, Akbay, Esra A, Hammerman, Peter S, Wong, Kwok-Kin, Dranoff, Glenn, Mori, Masahide, Kijima, Takashi, Kumanogoh, Atsushi

“…The PD-1-blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum…”
Get full text

Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study by Yamamoto, Yuji, Yano, Yukihiro, Kuge, Tomoki, Okabe, Fukuko, Ishijima, Mikako, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yamaguchi, Toshihiko, Mori, Masahide

“…Background Pirfenidone is an antifibrotic agent that is potentially effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, no study has…”
Get full text

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study by Yano, Yukihiro, Kurebe, Hiroyuki, Edahiro, Ryuya, Hosono, Yuki, Nakatsubo, Saeko, Nishida, Kohei, Sawa, Nobuyuki, Ishijima, Mikako, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yamaguchi, Toshihiko, Mori, Masahide

“…The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated. The…”
Get full text

Radiation Pneumonitis with Eosinophilic Alveolitis in a Lung Cancer Patient by Hosono, Yuki, Sawa, Nobuhiko, Nakatsubo, Saeko, Ishijima, Mikako, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide, Yamaguchi, Toshihiko, Yokota, Soichiro

“…A 59-year-old woman suffering from dry cough and dyspnea was admitted to our hospital. She had undergone concurrent chemo-radiotherapy five months earlier…”
Get full text

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib by Hara, Reina, Kanazu, Masaki, Iwai, Ami, Kuge, Tomoki, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

“…Here, we report a rare case involving a 66‐year‐old man with epidermal growth factor receptor (EGFR)‐mutant lung adenocarcinoma and antisynthetase syndrome…”
Get full text

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report by Kuge, Tomoki, Okabe, Fukuko, Yamamoto, Yuji, Ishijima, Mikako, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

“…Pulmonary pleomorphic carcinoma is a rare malignant tumor that grows rapidly and has a poor prognosis. Although no effective treatments have so far been…”
Get full text

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report by Edahiro, Ryuya, Ishijima, Mikako, Kurebe, Hiroyuki, Nishida, Kohei, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide

“…A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed…”
Get full text

Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung by Otsuka, Tomoyuki, Tanaka, Aya, Azukizawa, Hiroaki, Sasaki, Shoko, Ishijima, Mikako, Matsuki, Takanori, Osa, Akio, Nakatani, Takeshi, Kuroyama, Muneyoshi, Hirata, Haruhiko, Kijima, Takashi

“…We report a case of a 65-year-old woman with stage IV lung adenocarcinoma who experienced Stevens–Johnson syndrome (SJS) during afatinib therapy. The patient…”
Get full text

Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report by Uenami, Takeshi, Hosono, Yuki, Ishijima, Mikako, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide, Yamaguchi, Toshihiko, Yokota, Soichiro

“…Highlights • Treatment with immunotherapy can induce vitiligo in patients with melanoma. • We describe the first case of vitiligo associated with nivolumab in…”
Get full text

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series by Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

“…Background Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on…”
Get full text

Case series of pleomorphic carcinomas of the lung treated with nivolumab by Kanazu, Masaki, Uenami, Takeshi, Yano, Yukihiro, Nakatsubo, Saeko, Hosono, Yuki, Ishijima, Mikako, Akazawa, Yuki, Yamaguchi, Toshihiko, Urasaki, Koji, Mori, Masahide, Yokota, Soichiro

“…Pleomorphic carcinoma (PC) of the lung is a rare type of non‐small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and…”
Get full text

Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression by Uenami, Takeshi, Ishijima, Mikako, Kanazu, Masaki, Kurebe, Hiroyuki, Edahiro, Ryuya, Nishida, Kohei, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

“…Recently, the immune checkpoint inhibitor (ICI) pembrolizumab was demonstrated to be superior to platinum doublet chemotherapy in the first-line setting in…”
Get full text

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report by Edahiro, Ryuya, Ishijima, Mikako, Kurebe, Hiroyuki, Nishida, Kohei, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide

Get full text

Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series by Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

“…BACKGROUNDNivolumab is an anti-PD-1 blocking monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). However, some patients on…”
Get full text

Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression by Uenami, Takeshi, Ishijima, Mikako, Kanazu, Masaki, Kurebe, Hiroyuki, Edahiro, Ryuya, Nishida, Kohei, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide

Get full text

Case series of pleomorphic carcinomas of the lung treated with nivolumab by Kanazu, Masaki, Uenami, Takeshi, Yano, Yukihiro, Nakatsubo, Saeko, Hosono, Yuki, Ishijima, Mikako, Akazawa, Yuki, Yamaguchi, Toshihiko, Urasaki, Koji, Mori, Masahide, Yokota, Soichiro

“…Pleomorphic carcinoma (PC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and…”
Get full text

Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung by Otsuka, Tomoyuki, Tanaka, Aya, Azukizawa, Hiroaki, Sasaki, Shoko, Ishijima, Mikako, Matsuki, Takanori, Osa, Akio, Nakatani, Takeshi, Kuroyama, Muneyoshi, Hirata, Haruhiko, Kijima, Takashi

Get full text